As reported in the Journal of Clinical Oncology by Doi et al, pembrolizumab (Keytruda) showed activity in patients with previously treated advanced esophageal carcinoma in the phase Ib multicohort KEYNOTE-028 study.
http://www.ascopost.com/News/58296
Immunotherapy in Advanced Esophageal Carcinoma